NCT01175200

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Ascopharm Groupe Novasco · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatment/prevention of GI ulceration.

Conditions

• Anti Platelet Effects

Interventions

Type	Name	Description
DRUG	Clopidogrel	antiplatelet agent
DRUG	Prasugrel	antiplatelet agent
DRUG	Lansoprazole	proton pum inhibitor
DRUG	Placebo	placebo comparator similar to lansoprazole

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2010-08-04
• Last updated: 2012-07-04

Locations

1 site across 1 country: France